How to Implement Risk Management Principles and Activities Within a Quality Management System

Nov. 03 & 04, 2008, The Park Plaza Wallstreet, Berlin, Germany
The Center for Professional Innovation & Education has designed this two-day course for quality managers, engineers, auditors, regulatory/quality compliance professionals, production managers and top management interested in learning the value of Risk Management Principals and how to enhance existing systems by better utilizing resources through the optimization of risk management techniques.

This program will provide a broad introduction to the subject of risk management for more experienced personnel, including middle and upper management. It will allow participants to update and broaden their knowledge of US and International Risk Management requirements. It explores both the positive and negative aspects of risk and aims to improve knowledge and practical skills in the identification assessment and control of business risk.

Upon completion of this course, attendees will understand how to effectively meet the requirements of risk management for medical devices, pharmaceutical and biologics products and processes. Emphasis will be placed on the effective use of resources in a production and quality system environment by developing strategies based on risk.

The first day will cover the general context for risk management, required procedures and the discussion of the general ISO 14971, FDA, and GHTF requirements of risk management. The second day will discuss and apply several risk management techniques which will be covered as they relate to product and production processes.

For further information and registration, please visit:
http://www.cfpie.com/showitem.aspx?productid=041&source=wpnc

About The Center for Professional Innovation & Education (CfPIE)
The Center for Professional Innovation & Education is the global leader in accredited pharmaceutical training including courses on Biotech, Biopharmaceutical, Medical Device and Skin/Cosmetic product topics. With over 270 public courses and customized client-site training programs offered annually, CfPIE has a convenient option for personnel looking for both professional advancement and technical/regulatory training.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...